Scarica l'app Stockscreener
0.8673
2.19%
-0.0194
Precedente Chiudi:
$0.8867
Aprire:
$0.87
Volume 24 ore:
232.19K
Relative Volume:
0.41
Capitalizzazione di mercato:
$59.56M
Reddito:
-
Utile/perdita netta:
$-112.46M
Rapporto P/E:
-0.4272
EPS:
-2.03
Flusso di cassa netto:
$-99.89M
1 W Prestazione:
-12.50%
1M Prestazione:
+9.12%
6M Prestazione:
-27.73%
1 anno Prestazione:
-62.13%
Intervallo 1D:
$0.8443
$0.8817
Intervallo di 1 settimana:
$0.8301
$1.03
Portata 52W:
$0.63
$3.1399
Vor Biopharma Inc Stock (VOR) Company Profile
Nome
Vor Biopharma Inc
Settore
Industria
Telefono
617-655-6580
Indirizzo
100 CAMBRIDGEPARK DRIVE, CAMBRIDGE
Confronta VOR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VOR
Vor Biopharma Inc
|
0.8673 | 59.56M | 0 | -112.46M | -99.89M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Vor Biopharma Inc Stock (VOR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-07-26 | Iniziato | Wedbush | Outperform |
| 2022-04-27 | Iniziato | Goldman | Neutral |
| 2021-12-17 | Iniziato | H.C. Wainwright | Buy |
| 2021-12-03 | Iniziato | Robert W. Baird | Outperform |
| 2021-12-02 | Iniziato | Oppenheimer | Outperform |
| 2021-10-19 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-03-25 | Iniziato | B. Riley Securities | Buy |
| 2021-03-03 | Iniziato | Barclays | Overweight |
| 2021-03-03 | Iniziato | Evercore ISI | Outperform |
| 2021-03-02 | Iniziato | Goldman | Sell |
| 2021-03-02 | Iniziato | Stifel | Buy |
Mostra tutto
Vor Biopharma Inc Borsa (VOR) Ultime notizie
Vor Biopharma Inc. (NYSE:VOR) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Vor Biopharma Inc. (NYSE:VOR) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Vor Biopharma's SWOT analysis: stock shows promise amid AML treatment advances - Investing.com Canada
Vor Biopharma’s (VOR) Buy Rating Reiterated at HC Wainwright - Defense World
Vor Biopharma’s (VOR) “Outperform” Rating Reaffirmed at Wedbush - Defense World
Vor Biopharma Announces Updated Clinical Data and FDA Feedback – - Defense World
Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from Fda Regarding Registrational Trial Design - Marketscreener.com
Vor Biopharma : Bio Corporate Presentation December 2024 - Marketscreener.com
Vor Biopharma Reports Promising Phase 1/2 Study Results - TipRanks
Vor Bio Provides Clinical Update Further Validating - GlobeNewswire
Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design - Marketscreener.com
Vor Biopharma : A CD33 Deleted Allograft (Trem cel) Enables Post Hematopoietic Cell Transplant (HCT) Maintenance Dosing of Gemtuzumab Ozogamicin (GO) with Therapeutic Levels of Drug Exposure and Low Hematologic and Hepatic Toxicity in Patients - Marketscreener.com
Vor Biopharma : Multimodal atlas of paired diagnosis and relapse AML reveals surface antigens for multi-specific immunotherapy - Marketscreener.com
Omeros Corp (OMER) Stock Surges Amidst Biotech Sector Activity - GuruFocus.com
Vor Biopharma Inc. (NYSE:VOR) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Stock Traders Purchase High Volume of Archer Aviation Call Options (NYSE:ACHR) - Defense World
Navigator Holdings Ltd. (NYSE:NVGS) Given Consensus Rating of “Buy” by Brokerages - Defense World
Astrana Health, Inc. (NASDAQ:ASTH) Receives Consensus Rating of “Buy” from Analysts - Defense World
Vor Biopharma Inc. (NYSE:VOR) Given Consensus Rating of “Buy” by Analysts - Defense World
Kosmos Energy Ltd. (NYSE:KOS) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Annovis Bio, Inc. (NYSE:ANVS) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
VOR Biopharma's SWOT analysis: stock shows promise amid clinical progress - Investing.com Nigeria
Vor Bio to Participate in the Stifel 2024 Healthcare Conference - GlobeNewswire
Vor Bio to Present at Stifel Healthcare Conference, Host Key Investor Meetings | VOR Stock News - StockTitan
Robert W. Baird Lowers Vor Biopharma (NYSE:VOR) Price Target to $14.00 - Defense World
Vor Biopharma (NYSE:VOR) Given “Buy” Rating at HC Wainwright - Defense World
Vor Biopharma’s (VOR) “Outperform” Rating Reiterated at Wedbush - Defense World
Vor Biopharma (NYSE:VOR) Receives Outperform Rating from Wedbush - MarketBeat
Vor Biopharma (NYSE:VOR) Earns Buy Rating from HC Wainwright - MarketBeat
Vor Biopharma (NYSE:VOR) Price Target Lowered to $14.00 at Robert W. Baird - MarketBeat
Vor Biopharma Reports Q3 2024 Financial Results - TipRanks
Vor Biopharma : Bio Corporate Presentation November 2024 - Marketscreener.com
Vor Biopharma Inc. (VOR) Reports In-Line Q3 EPS - StreetInsider.com
Vor Bio Reports Third Quarter 2024 Financial Results and Provides Company Update - GlobeNewswire
Vor Biopharma : SITC – 2024 – POSTER PRESENTATION 1092 - Marketscreener.com
Vor Biopharma : ESGCT – 2024 – Oral Presentation OR085 - Marketscreener.com
Allogeneic Hematopoietic Stem Cell Transplant Market to - GlobeNewswire
Scrip Asks…What Does 2023 Hold For Biopharma? Part 5: Technological Advances - Citeline News & Insights
Closing Strong: Vor Biopharma Inc (VOR) Ends at 0.64, Down -3.04 from Last Close - The Dwinnex
Recent Insider Activity Could Benefit Vor Biopharma Inc (VOR) - Knox Daily
Analyzing Chemours Company (CC) After Recent Trading Activity - Knox Daily
Insider Selling Buzz: Vor Biopharma Inc [VOR] CHIEF MEDICAL OFFICER Attar Eyal C. sold 14,645 shares of the company – Knox Daily - Knox Daily
Closing Figures: Vor Biopharma Inc (VOR)’s Positive Finish at 0.69, Up 2.80 - The Dwinnex
An Analysis of Vor Biopharma Inc (VOR)’s Potential Price Growth - Knox Daily
Vor Biopharma Inc (VOR) Stock: From Low to High in 52 Weeks - The InvestChronicle
How does Vor Biopharma Inc (VOR) change from a tortoise to a hare? - SETE News
Vor Biopharma's SWOT analysis: oncology stock shows promise amid challenges - Investing.com
Vor Bio appoints new CFO amid clinical advancements - Investing.com India
Vor Biopharma Inc (VOR) deserves closer scrutiny - US Post News
Vor Biopharma Inc. Appoints Han Choi as Chief Financial Officer - Marketscreener.com
Metric Analysis: Vor Biopharma Inc (VOR)’s Key Ratios in the Limelight - The Dwinnex
Vor Biopharma Inc Azioni (VOR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):